CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia

Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia

(2009) Charles G. Mullighan et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy

(2008) M. N. Dworzak et al.   BLOOD

Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells

(2008) Giuseppe Gaipa et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia

(2008) T Flohr et al.   LEUKEMIA

Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction

(2008) R Ratei et al.   LEUKEMIA

Treatment of Childhood Acute Lymphoblastic Leukemia

(2008) Martin Stanulla et al.   SEMINARS IN HEMATOLOGY